Horner has more than 40 years of industry experience gained with biotech and big pharma companies. He was most recently ceo of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in 2008.
Prior to joining Prestwick, Horner was ceo of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for US$1.9bn in 2005. He also worked for Ligand Pharmaceuticals following a career at Abbott Laboratories where rose to president of the company’s business in Canada.
‘I have been attracted to this opportunity by the company’s rich pipeline of clinical and pre-clinical drug candidates focused on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders,’ said Horner.
Dermatology specialist appoints chairman
George Horner joins Creabilis of Luxembourg
You may also like
Sustainability
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security